Company Profile
ProKidney Stock Price, News & Catalysts
- Ticker:
- PROK
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.61 USD (+13.38%)
Close
Last updated: August 21, 2026
390M USD
Market cap
Why the stock is moving
As of Aug 21, 2026, PROK closed up 13.4% at $1.61. No new same-company headline was identified in the current news window.
Company overview
Regenerative Kidney Medicine
ProKidney develops cell therapies intended to preserve kidney function and delay progression to kidney failure. Its work focuses on patients with advanced chronic kidney disease and type 2 diabetes who face a high risk of dialysis or transplantation.
Rilparencel
Rilparencel, also known as REACT, is a proprietary autologous cell therapy manufactured from a patient's own kidney cells. The product has Regenerative Medicine Advanced Therapy designation and is designed to restore or stabilize kidney function through repeat image-guided injections.
Phase 3 Development
The Phase 3 REGEN-006, or PROACT 1, study evaluates rilparencel against a sham procedure. Its design supports an accelerated-approval analysis based on annualized eGFR slope and a longer confirmatory analysis based on kidney-function decline, dialysis, transplantation, or renal and cardiovascular death.
Future catalysts
- Completion of full enrollment in the Phase 3 REGEN-006 study in the second half of 2026.
- Topline results from the accelerated-approval efficacy analysis of REGEN-006 in the second quarter of 2027.
- Topline results from the confirmatory composite time-to-event analysis of REGEN-006 in the second half of 2029.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of ProKidney (PROK)?
ProKidney (PROK) most recently closed at 1.61 USD, a +13.38% move versus the previous session.
What is the market cap of ProKidney (PROK)?
ProKidney currently has a market capitalization of 390M USD on BioPharmSignal.
What does ProKidney do?
Regenerative Kidney Medicine ProKidney develops cell therapies intended to preserve kidney function and delay progression to kidney failure. Its work focuses on patients with advanced chronic kidney disease and type 2 diabetes who face a high risk of dialysis or transplantation. Rilparencel Rilparencel, also known as REACT, is a proprietary autologous cell...
On which exchange is PROK stock listed?
ProKidney (PROK) is associated with NASDAQ, United States, Biopharma.
What is REGEN-006?
Completion of full enrollment in the Phase 3 REGEN-006 study in the second half of 2026.
Which conditions is ProKidney targeting with REGEN-006?
ProKidney is associated with cardiovascular disease, diabetes based on its company overview and current catalyst commentary.
How does ProKidney describe recent progress with REGEN-006?
Completion of full enrollment in the Phase 3 REGEN-006 study in the second half of 2026.
What is Regenerative?
Regenerative Kidney Medicine ProKidney develops cell therapies intended to preserve kidney function and delay progression to kidney failure.